Faculty

Back to Index
Paul S. Gaynon, MD
Professor of Pediatrics
Pediatrics
CHL Mail Stop 54 Off Campus Los Angeles
+1 323 361 2163

Publications

Cooper TM, Cassar J, Eckroth E, Malvar J, Sposto R, Gaynon P, Chang BH, Gore L, August K, Pollard JA, DuBois SG, Silverman LB, Oesterheld J, Gammon G, Magoon D, Annesley C, Brown PA. A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Clin Cancer Res. 2016 Aug 15; 22(16):4014-22. View in: PubMed

Yeo KK, Gaynon PS, Fu CH, Wayne AS, Sun W. Bortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV): An Active Reinduction Regimen for Children With Relapsed Acute Lymphoblastic Leukemia and Asparaginase Intolerance. J Pediatr Hematol Oncol. 2016 Jul; 38(5):345-9. View in: PubMed

Gaynon PS, Sun W. Oligoclonality and new agent evaluation in acute lymphoblastic leukaemia. Br J Haematol. 2016 Jun; 173(6):950-7. View in: PubMed

Parekh C, Gaynon PS, Abdel-Azim H. Reply: T-Cell Acute Lymphoblastic Leukemia, Minimal Residual Disease, and Lymphocyte Recovery. Pediatr Blood Cancer. 2016 May; 63(5):945. View in: PubMed

Matloub Y, Stork L, Asselin B, Hunger SP, Borowitz M, Jones T, Bostrom B, Gastier-Foster JM, Heerema NA, Carroll A, Winick N, Carroll WL, Camitta B, Devidas M, Gaynon PS. Outcome of Children with Standard-Risk T-Lineage Acute Lymphoblastic Leukemia-Comparison among Different Treatment Strategies. Pediatr Blood Cancer. 2016 Feb; 63(2):255-61. View in: PubMed

Meeske KA, Ji L, Freyer DR, Gaynon P, Ruccione K, Butturini A, Avramis VI, Siegel S, Matloub Y, Seibel NL, Sposto R. Comparative Toxicity by Sex Among Children Treated for Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. Pediatr Blood Cancer. 2015 Dec; 62(12):2140-9. View in: PubMed

Ko RH, Jones TL, Radvinsky D, Robison N, Gaynon PS, Panosyan EH, Avramis IA, Avramis VI, Rubin J, Ettinger LJ, Seibel NL, Dhall G. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report. Cancer. 2015 Dec 1; 121(23):4205-11. View in: PubMed

Parekh C, Gaynon PS, Abdel-Azim H. End of induction minimal residual disease alone is not a useful determinant for risk stratified therapy in pediatric T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015 Nov; 62(11):2040-3. View in: PubMed

Gaynon PS. ALL and osteonecrosis. Blood. 2015 Oct 8; 126(15):1734-5. View in: PubMed

Meany HJ, Seibel NL, Krailo M, Villaluna D, Chen Z, Gaynon P, Neglia JP, Park JR, Hutchinson R, Sato JK, Wells RJ, Woods WG, Reaman G. Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group. J Immunother. 2015 Sep; 38(7):299-305. View in: PubMed

Sun W, Gaynon PS, Sposto R, Wayne AS. Improving access to novel agents for childhood leukemia. Cancer. 2015 Jun 15; 121(12):1927-36. View in: PubMed

Hastings C, Gaynon PS, Nachman JB, Sather HN, Lu X, Devidas M, Seibel NL. Increased post-induction intensification improves outcome in children and adolescents with a markedly elevated white blood cell count (=200 × 10(9) /l) with T cell acute lymphoblastic leukaemia but not B cell disease: a report from the Children's Oncology Group. Br J Haematol. 2015 Feb; 168(4):533-46. View in: PubMed

Raetz EA, Morrison D, Romanos-Sirakis E, Gaynon P, Sposto R, Bhojwani D, Bostrom BC, Brown P, Eckroth E, Cassar J, Malvar J, Buchbinder A, Carroll WL. A Phase I Study of EZN-3042, a Novel Survivin Messenger Ribonucleic Acid (mRNA) Antagonist, Administered in Combination With Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL): A Report From the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. J Pediatr Hematol Oncol. 2014 Aug; 36(6):458-63. View in: PubMed

Myers DE, Yiv S, Qazi S, Ma H, Cely I, Shahidzadeh A, Arellano M, Finestone E, Gaynon PS, Termuhlen A, Cheng J, Uckun FM. CD19-antigen specific nanoscale liposomal formulation of a SYK P-site inhibitor causes apoptotic destruction of human B-precursor leukemia cells. Integr Biol (Camb). 2014 Jul 21; 6(8):766-80. View in: PubMed

Schultz KR, Carroll A, Heerema NA, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, Zheng HW, Davies SM, Gaynon PS, Trigg M, Rutledge R, Jorstad D, Winick N, Borowitz MJ, Hunger SP, Carroll WL, Camitta B. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031. Leukemia. 2014 Jul; 28(7):1467-71. View in: PubMed

Orgel E, Sposto R, Malvar J, Seibel NL, Ladas E, Gaynon PS, Freyer DR. Impact on Survival and Toxicity by Duration of Weight Extremes During Treatment for Pediatric Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. J Clin Oncol. 2014 May 1; 32(13):1331-7. View in: PubMed

Schultz KR, Devidas M, Bowman WP, Aledo A, Slayton WB, Sather H, Zheng HW, Davies SM, Gaynon PS, Trigg M, Rutledge R, Jorstad D, Carroll AJ, Heerema N, Winick N, Borowitz MJ, Hunger SP, Carroll WL, Camitta B. Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children's Oncology Group Study AALL0031. Leukemia. 2014 Apr; 28(4):964-7. View in: PubMed

Liu Y, Tang J, Wakamatsu P, Xue H, Chen J, Gaynon PS, Shen S, Sun W. High-resolution melting curve analysis, a rapid and affordable method for mutation analysis in childhood acute myeloid leukemia. Front Pediatr. 2014; 2:96. View in: PubMed

Asselin BL, Gaynon P, Whitlock JA. Recent advances in acute lymphoblastic leukemia in children and adolescents: an expert panel discussion. Curr Opin Oncol. 2013 Dec; 25 Suppl 3:S1-S13. View in: PubMed

Acree SC, Tovar JP, Pattengale PK, Wang LL, Church JA, Gaynon PS, Cassarino DS. Subcutaneous Panniculitis-like T-cell lymphoma in two pediatric patients: an HIV-positive adolescent and a 4-month-old infant. Fetal Pediatr Pathol. 2013 Jun; 32(3):175-83. View in: PubMed

Uckun FM, Qazi S, Cely I, Sahin K, Shahidzadeh A, Ozercan I, Yin Q, Gaynon P, Termuhlen A, Cheng J, Yiv S. Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia. Blood. 2013 May 23; 121(21):4348-54. View in: PubMed

Masera G, Conter V, Gaynon PS. The principle and practice of reinduction therapy (in ALL): repetita iuvant! Klin Padiatr. 2013 May; 225 Suppl 1:S57-61. View in: PubMed

Gaynon P. Once upon a time--a personal view on episodes in leukemia research in Germany, and beyond. Klin Padiatr. 2013 May; 225 Suppl 1:S5. View in: PubMed

Uckun FM, Ma H, Ishkhanian R, Arellano M, Shahidzadeh A, Termuhlen A, Gaynon PS, Qazi S. Constitutive Function of the Ikaros Transcription Factor in Primary Leukemia Cells from Pediatric Newly Diagnosed High-Risk and Relapsed B-precursor ALL Patients. PLoS One. 2013; 8(11):e80732. View in: PubMed

Gaynon PS, Harned TM. ABT-751 in relapsed childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2012 Oct; 34(7):583-4. View in: PubMed

Lindsay H, Gaynon P. Anaphylactic reaction to etoposide phosphate. Pediatr Blood Cancer. 2012 Oct; 59(4):765. View in: PubMed

Mattano LA, Devidas M, Nachman JB, Sather HN, Hunger SP, Steinherz PG, Gaynon PS, Seibel NL. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. Lancet Oncol. 2012 Sep; 13(9):906-15. View in: PubMed

Messinger YH, Gaynon PS, Sposto R, van der Giessen J, Eckroth E, Malvar J, Bostrom BC. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Blood. 2012 Jul 12; 120(2):285-90. View in: PubMed

Oliansky DM, Camitta B, Gaynon P, Nieder ML, Parsons SK, Pulsipher MA, Dillon H, Ratko TA, Wall D, McCarthy PL, Hahn T. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. ASBMT Position Statement. Biol Blood Marrow Transplant. 2012 Jul; 18(7):979-81. View in: PubMed

Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, Reaman GH, Carroll WL. Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group. J Clin Oncol. 2012 May 10; 30(14):1663-9. View in: PubMed

Schrappe M, Hunger SP, Pui CH, Saha V, Gaynon PS, Baruchel A, Conter V, Otten J, Ohara A, Versluys AB, Escherich G, Heyman M, Silverman LB, Horibe K, Mann G, Camitta BM, Harbott J, Riehm H, Richards S, Devidas M, Zimmermann M. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med. 2012 Apr 12; 366(15):1371-81. View in: PubMed

Oliansky DM, Camitta B, Gaynon P, Nieder ML, Parsons SK, Pulsipher MA, Dillon H, Ratko TA, Wall D, McCarthy PL, Hahn T. Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. Biol Blood Marrow Transplant. 2012 Apr; 18(4):505-22. View in: PubMed

Ma H, Qazi S, Ozer Z, Gaynon P, Reaman GH, Uckun FM. CD22 Exon 12 deletion is a characteristic genetic defect of therapy-refractory clones in paediatric acute lymphoblastic leukaemia. Br J Haematol. 2012 Jan; 156(1):89-98. View in: PubMed

Hijiya N, Thomson B, Isakoff MS, Silverman LB, Steinherz PG, Borowitz MJ, Kadota R, Cooper T, Shen V, Dahl G, Thottassery JV, Jeha S, Maloney K, Paul JA, Barry E, Carroll WL, Gaynon PS. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 2011 Dec 1; 118(23):6043-9. View in: PubMed

Gaynon PS. A remembrance: James B. Nachman 1948-2011. Pediatr Blood Cancer. 2011 Oct; 57(4):533-4. View in: PubMed

Gaynon PS. James B. Nachman, 1948 to 2011: a remembrance. J Pediatr Hematol Oncol. 2011 Aug; 33(6):403-5. View in: PubMed

Matloub Y, Bostrom BC, Hunger SP, Stork LC, Angiolillo A, Sather H, La M, Gastier-Foster JM, Heerema NA, Sailer S, Buckley PJ, Thomson B, Cole C, Nachman JB, Reaman G, Winick N, Carroll WL, Devidas M, Gaynon PS. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2011 Jul 14; 118(2):243-51. View in: PubMed

Bonate PL, Cunningham CC, Gaynon P, Jeha S, Kadota R, Lam GN, Razzouk B, Rytting M, Steinherz P, Weitman S. Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer. Cancer Chemother Pharmacol. 2011 Apr; 67(4):875-90. View in: PubMed

Freyer DR, Devidas M, La M, Carroll WL, Gaynon PS, Hunger SP, Seibel NL. Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group. Blood. 2011 Mar 17; 117(11):3010-5. View in: PubMed

Gorman MF, Ji L, Ko RH, Barnette P, Bostrom B, Hutchinson R, Raetz E, Seibel NL, Twist CJ, Eckroth E, Sposto R, Gaynon PS, Loh ML. Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study. Pediatr Blood Cancer. 2010 Sep; 55(3):421-9. View in: PubMed

Messinger Y, Gaynon P, Raetz E, Hutchinson R, Dubois S, Glade-Bender J, Sposto R, van der Giessen J, Eckroth E, Bostrom BC. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer. 2010 Aug; 55(2):254-9. View in: PubMed

Horton TM, Sposto R, Brown P, Reynolds CP, Hunger SP, Winick NJ, Raetz EA, Carroll WL, Arceci RJ, Borowitz MJ, Gaynon PS, Gore L, Jeha S, Maurer BJ, Siegel SE, Biondi A, Kearns PR, Narendran A, Silverman LB, Smith MA, Zwaan CM, Whitlock JA. Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference. Pediatr Blood Cancer. 2010 Jul 1; 54(7):872-8. View in: PubMed

Stork LC, Matloub Y, Broxson E, La M, Yanofsky R, Sather H, Hutchinson R, Heerema NA, Sorrell AD, Masterson M, Bleyer A, Gaynon PS. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial. Blood. 2010 Apr 8; 115(14):2740-8. View in: PubMed

Ko RH, Ji L, Barnette P, Bostrom B, Hutchinson R, Raetz E, Seibel NL, Twist CJ, Eckroth E, Sposto R, Gaynon PS, Loh ML. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol. 2010 Feb 1; 28(4):648-54. View in: PubMed

Gaynon PS, Angiolillo AL, Carroll WL, Nachman JB, Trigg ME, Sather HN, Hunger SP, Devidas M. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report. Leukemia. 2010 Feb; 24(2):285-97. View in: PubMed

Hijiya N, Gaynon P, Barry E, Silverman L, Thomson B, Chu R, Cooper T, Kadota R, Rytting M, Steinherz P, Shen V, Jeha S, Abichandani R, Carroll WL. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia. 2009 Dec; 23(12):2259-64. View in: PubMed

Armenian SH, Nash KA, Kapoor N, Franklin JL, Gaynon PS, Ross LA, Hoffman JA. Prospective monitoring for invasive aspergillosis using galactomannan and polymerase chain reaction in high risk pediatric patients. J Pediatr Hematol Oncol. 2009 Dec; 31(12):920-6. View in: PubMed

Nachman JB, La MK, Hunger SP, Heerema NA, Gaynon PS, Hastings C, Mattano LA, Sather H, Devidas M, Freyer DR, Steinherz PG, Seibel NL. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group. J Clin Oncol. 2009 Nov 1; 27(31):5189-94. View in: PubMed

Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, Wang C, Davies SM, Gaynon PS, Trigg M, Rutledge R, Burden L, Jorstad D, Carroll A, Heerema NA, Winick N, Borowitz MJ, Hunger SP, Carroll WL, Camitta B. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol. 2009 Nov 1; 27(31):5175-81. View in: PubMed

Sposto R, Gaynon PS. An adjustment for patient heterogeneity in the design of two-stage phase II trials. Stat Med. 2009 Sep 10; 28(20):2566-79. View in: PubMed

Jeha S, Razzouk B, Rytting M, Rheingold S, Albano E, Kadota R, Luchtman-Jones L, Bomgaars L, Gaynon P, Goldman S, Ritchey K, Arceci R, Altman A, Stine K, Steinherz L, Steinherz P. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol. 2009 Sep 10; 27(26):4392-7. View in: PubMed

Nguyen K, Devidas M, Cheng SC, La M, Raetz EA, Carroll WL, Winick NJ, Hunger SP, Gaynon PS, Loh ML. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia. 2008 Dec; 22(12):2142-50. View in: PubMed

Harned TM, Gaynon P. Relapsed acute lymphoblastic leukemia: current status and future opportunities. Curr Oncol Rep. 2008 Nov; 10(6):453-8. View in: PubMed

Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P, Larson RA, Nachman J. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008 Sep 1; 112(5):1646-54. View in: PubMed

Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ, Camitta BM, Gaynon PS, Carroll WL. Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. J Clin Oncol. 2008 Aug 20; 26(24):3971-8. View in: PubMed

Trigg ME, Sather HN, Reaman GH, Tubergen DG, Steinherz PG, Gaynon PS, Uckun FM, Hammond GD. Ten-year survival of children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leuk Lymphoma. 2008 Jun; 49(6):1142-54. View in: PubMed

Harned TM, Gaynon PS. Treating refractory leukemias in childhood, role of clofarabine. Ther Clin Risk Manag. 2008 Apr; 4(2):327-36. View in: PubMed

Seibel NL, Steinherz PG, Sather HN, Nachman JB, Delaat C, Ettinger LJ, Freyer DR, Mattano LA, Hastings CA, Rubin CM, Bertolone K, Franklin JL, Heerema NA, Mitchell TL, Pyesmany AF, La MK, Edens C, Gaynon PS. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008 Mar 1; 111(5):2548-55. View in: PubMed

Malempati S, Gaynon PS, Sather H, La MK, Stork LC. Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952. J Clin Oncol. 2007 Dec 20; 25(36):5800-7. View in: PubMed

Gaynon PS. Treatment of pediatric acute lymphoblastic leukemia: progress achieved and challenges remaining. Curr Hematol Malig Rep. 2007 Jul; 2(3):193-201. View in: PubMed

Heerema NA, Raimondi SC, Anderson JR, Biegel J, Camitta BM, Cooley LD, Gaynon PS, Hirsch B, Magenis RE, McGavran L, Patil S, Pettenati MJ, Pullen J, Rao K, Roulston D, Schneider NR, Shuster JJ, Sanger W, Sutcliffe MJ, van Tuinen P, Watson MS, Carroll AJ. Specific extra chromosomes occur in a modal number dependent pattern in pediatric acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2007 Jul; 46(7):684-93. View in: PubMed

Butturini AM, Dorey FJ, Lange BJ, Henry DW, Gaynon PS, Fu C, Franklin J, Siegel SE, Seibel NL, Rogers PC, Sather H, Trigg M, Bleyer WA, Carroll WL. Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2007 May 20; 25(15):2063-9. View in: PubMed

Schultz KR, Pullen DJ, Sather HN, Shuster JJ, Devidas M, Borowitz MJ, Carroll AJ, Heerema NA, Rubnitz JE, Loh ML, Raetz EA, Winick NJ, Hunger SP, Carroll WL, Gaynon PS, Camitta BM. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood. 2007 Feb 1; 109(3):926-35. View in: PubMed

Matloub Y, Lindemulder S, Gaynon PS, Sather H, La M, Broxson E, Yanofsky R, Hutchinson R, Heerema NA, Nachman J, Blake M, Wells LM, Sorrell AD, Masterson M, Kelleher JF, Stork LC. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group. Blood. 2006 Aug 15; 108(4):1165-73. View in: PubMed

Jarrar M, Gaynon PS, Periclou AP, Fu C, Harris RE, Stram D, Altman A, Bostrom B, Breneman J, Steele D, Trigg M, Zipf T, Avramis VI. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941). Pediatr Blood Cancer. 2006 Aug; 47(2):141-6. View in: PubMed

Gaynon PS, Harris RE, Altman AJ, Bostrom BC, Breneman JC, Hawks R, Steele D, Zipf T, Stram DO, Villaluna D, Trigg ME. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941. J Clin Oncol. 2006 Jul 1; 24(19):3150-6. View in: PubMed

Jeha S, Gaynon PS, Razzouk BI, Franklin J, Kadota R, Shen V, Luchtman-Jones L, Rytting M, Bomgaars LR, Rheingold S, Ritchey K, Albano E, Arceci RJ, Goldman S, Griffin T, Altman A, Gordon B, Steinherz L, Weitman S, Steinherz P. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. 2006 Apr 20; 24(12):1917-23. View in: PubMed

Gaynon PS. Treatment adherence and 6-mercaptopurine metabolites. Pediatr Blood Cancer. 2006 Feb; 46(2):120-1. View in: PubMed

Hahn T, Wall D, Camitta B, Davies S, Dillon H, Gaynon P, Larson RA, Parsons S, Seidenfeld J, Weisdorf D, McCarthy PL. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant. 2006 Jan; 12(1):1-30. View in: PubMed

Whitlock JA, Sather HN, Gaynon P, Robison LL, Wells RJ, Trigg M, Heerema NA, Bhatia S. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2005 Dec 15; 106(13):4043-9. View in: PubMed

Gaynon PS. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol. 2005 Dec; 131(5):579-87. View in: PubMed

Hahn T, Wall D, Camitta B, Davies S, Dillon H, Gaynon P, Larson RA, Parsons S, Seidenfeld J, Weisdorf D, McCarthy PL. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review. Biol Blood Marrow Transplant. 2005 Nov; 11(11):823-61. View in: PubMed

Aricó M, Baruchel A, Bertrand Y, Biondi A, Conter V, Eden T, Gadner H, Gaynon P, Horibe K, Hunger SP, Janka-Schaub G, Masera G, Nachman J, Pieters R, Schrappe M, Schmiegelow K, Valsecchi MG, Pui CH. The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, January 29--30, 2005. Leukemia. 2005 Jul; 19(7):1145-52. View in: PubMed

Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M, Billett A, Kurtzberg J, Reaman G, Gaynon P, Whitlock J, Krailo M, Harris MB. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol. 2005 May 20; 23(15):3376-82. View in: PubMed

Sutcliffe MJ, Shuster JJ, Sather HN, Camitta BM, Pullen J, Schultz KR, Borowitz MJ, Gaynon PS, Carroll AJ, Heerema NA. High concordance from independent studies by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI Standard-Risk B-precursor Acute Lymphoblastic Leukemia: a Children's Oncology Group (COG) initiative. Leukemia. 2005 May; 19(5):734-40. View in: PubMed

Moorman AV, Raimondi SC, Pui CH, Baruchel A, Biondi A, Carroll AJ, Forestier E, Gaynon PS, Harbott J, Harms DO, Heerema N, Pieters R, Schrappe M, Silverman LB, Vilmer E, Harrison CJ. No prognostic effect of additional chromosomal abnormalities in children with acute lymphoblastic leukemia and 11q23 abnormalities. Leukemia. 2005 Apr; 19(4):557-63. View in: PubMed

Bassal M, La MK, Whitlock JA, Sather HN, Heerema NA, Gaynon PS, Stork LC. Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatr Blood Cancer. 2005 Jan; 44(1):21-8. View in: PubMed

Tognoni G, Masera G, Pui CH, Eden T, Nachman J, Gadner H, Gaynon PS, Evans WE, Schrappe M. Statement by members of the Ponte di Legno group on the right of children with leukemia to have full access to essential treatment for acute lymphoblastic leukemia. Ann Oncol. 2005 Jan; 16(1):169-70. View in: PubMed

Bonate PL, Craig A, Gaynon P, Gandhi V, Jeha S, Kadota R, Lam GN, Plunkett W, Razzouk B, Rytting M, Steinherz P, Weitman S. Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J Clin Pharmacol. 2004 Nov; 44(11):1309-22. View in: PubMed

Masera G, Eden T, Schrappe M, Nachman J, Gadner H, Gaynon P, Evans WE, Pui CH. Statement by members of the Ponte di Legno Group on the right of children to have full access to essential treatment for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2004 Aug; 43(2):103-4. View in: PubMed

Pui CH, Schrappe M, Masera G, Nachman J, Gadner H, Eden OB, Evans WE, Gaynon P. Ponte di Legno Working Group: statement on the right of children with leukemia to have full access to essential treatment and report on the Sixth International Childhood Acute Lymphoblastic Leukemia Workshop. Leukemia. 2004 Jun; 18(6):1043-53. View in: PubMed

Heerema NA, Nachman JB, Sather HN, La MK, Hutchinson R, Lange BJ, Bostrom B, Steinherz PG, Gaynon PS, Uckun FM. Deletion of 7p or monosomy 7 in pediatric acute lymphoblastic leukemia is an adverse prognostic factor: a report from the Children's Cancer Group. Leukemia. 2004 May; 18(5):939-47. View in: PubMed

Heerema NA, Harbott J, Galimberti S, Camitta BM, Gaynon PS, Janka-Schaub G, Kamps W, Basso G, Pui CH, Schrappe M, Auclerc MF, Carroll AJ, Conter V, Harrison CJ, Pullen J, Raimondi SC, Richards S, Riehm H, Sather HN, Shuster JJ, Silverman LB, Valsecchi MG, Aricò M. Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia. 2004 Apr; 18(4):693-702. View in: PubMed

Perentesis JP, Bhatia S, Boyle E, Shao Y, Shu XO, Steinbuch M, Sather HN, Gaynon P, Kiffmeyer W, Envall-Fox J, Robison LL. RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia. Leukemia. 2004 Apr; 18(4):685-92. View in: PubMed

Panosyan EH, Seibel NL, Martin-Aragon S, Gaynon PS, Avramis IA, Sather H, Franklin J, Nachman J, Ettinger LJ, La M, Steinherz P, Cohen LJ, Siegel SE, Avramis VI. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol. 2004 Apr; 26(4):217-26. View in: PubMed

Grigoryan RS, Panosyan EH, Seibel NL, Gaynon PS, Avramis IA, Avramis VI. Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961). In Vivo. 2004 Mar-Apr; 18(2):107-12. View in: PubMed

Panosyan EH, Grigoryan RS, Avramis IA, Seibel NL, Gaynon PS, Siegel SE, Fingert HJ, Avramis VI. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). Anticancer Res. 2004 Mar-Apr; 24(2C):1121-5. View in: PubMed

Reid GS, Terrett L, Alessandri AJ, Grubb S, Stork L, Seibel N, Gaynon P, Schultz KR. Altered patterns of T cell cytokine production induced by relapsed pre-B ALL cells. Leuk Res. 2003 Dec; 27(12):1135-42. View in: PubMed

Levy AS, Sather HN, Steinherz PG, Sowers R, La M, Moscow JA, Gaynon PS, Uckun FM, Bertino JR, Gorlick R. Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study. J Pediatr Hematol Oncol. 2003 Sep; 25(9):688-95. View in: PubMed

Wu SQ, Weinberg KI, Joo WJ, Quinn JJ, Franklin J, Siegel SE, Gaynon PS. Preponderant mitotic activity of nonleukemic cells plays an important role in failures to detect abnormal clone in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2003 Jul; 25(7):520-5. View in: PubMed

Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K, Erdmann GR, Gold S, Heerema NA, Hutchinson RJ, Provisor AJ, Trigg ME. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2003 May 15; 101(10):3809-17. View in: PubMed

Hutchinson RJ, Gaynon PS, Sather H, Bertolone SJ, Cooper HA, Tannous R, Wells LM, Heerema NA, Sailer S, Trigg ME. Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children's Cancer Group Trial 1881. J Clin Oncol. 2003 May 1; 21(9):1790-7. View in: PubMed

Clarke M, Gaynon P, Hann I, Harrison G, Masera G, Peto R, Richards S. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol. 2003 May 1; 21(9):1798-809. View in: PubMed

Pui CH, Chessells JM, Camitta B, Baruchel A, Biondi A, Boyett JM, Carroll A, Eden OB, Evans WE, Gadner H, Harbott J, Harms DO, Harrison CJ, Harrison PL, Heerema N, Janka-Schaub G, Kamps W, Masera G, Pullen J, Raimondi SC, Richards S, Riehm H, Sallan S, Sather H, Shuster J, Silverman LB, Valsecchi MG, Vilmer E, Zhou Y, Gaynon PS, Schrappe M. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia. 2003 Apr; 17(4):700-6. View in: PubMed

Bhatia S, Sather HN, Heerema NA, Trigg ME, Gaynon PS, Robison LL. Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. Blood. 2002 Sep 15; 100(6):1957-64. View in: PubMed

Gaynon PS. Response to Donadieu and Hill "Clinical trials in childhood acute lymphoblastic leukemia: a common prognostic classification and a common induction therapy are now warranted". J Pediatr Hematol Oncol. 2002 Aug-Sep; 24(6):426-8. View in: PubMed

Davies SM, Bhatia S, Ross JA, Kiffmeyer WR, Gaynon PS, Radloff GA, Robison LL, Perentesis JP. Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood. 2002 Jul 1; 100(1):67-71. View in: PubMed

Bhatia S, Sather HN, Pabustan OB, Trigg ME, Gaynon PS, Robison LL. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood. 2002 Jun 15; 99(12):4257-64. View in: PubMed

Pui CH, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W, Silverman LB, Biondi A, Harms DO, Vilmer E, Schrappe M, Camitta B. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet. 2002 Jun 1; 359(9321):1909-15. View in: PubMed

Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ, Ettinger AG, Ettinger LJ, Franklin J, Gaynon PS, Hilden JM, Lange B, Majlessipour F, Mathew P, Needle M, Neglia J, Reaman G, Holcenberg JS, Stork L. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2002 Mar 15; 99(6):1986-94. View in: PubMed

Gaynon PS. From where do clinical trials come? J Pediatr Hematol Oncol. 2002 Mar-Apr; 24(3):172-4. View in: PubMed

Kurre HA, Ettinger AG, Veenstra DL, Gaynon PS, Franklin J, Sencer SF, Reaman GH, Lange BJ, Holcenberg JS. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962). J Pediatr Hematol Oncol. 2002 Mar-Apr; 24(3):175-81. View in: PubMed

Heerema NA, Sather HN, Sensel MG, La MK, Hutchinson RJ, Nachman JB, Reaman GH, Lange BJ, Steinherz PG, Bostrom BC, Gaynon PS, Uckun FM. Abnormalities of chromosome bands 15q13-15 in childhood acute lymphoblastic leukemia. Cancer. 2002 Feb 15; 94(4):1102-10. View in: PubMed

Uckun FM, Pallisgaard N, Hokland P, Navara C, Narla R, Gaynon PS, Sather H, Heerema N. Expression of TEL-AML1 fusion transcripts and response to induction therapy in standard risk acute lymphoblastic leukemia. Leuk Lymphoma. 2001 Jun; 42(1-2):41-56. View in: PubMed

Gaynon PS, Bostrom BC, Hutchinson RJ, Lange BJ, Nachman JB, Steinherz PG, Sensel MG, Lee MK, Stram DO, Sather HN. Duration of hospitalization as a measure of cost on Children's Cancer Group acute lymphoblastic leukemia studies. J Clin Oncol. 2001 Apr 1; 19(7):1916-25. View in: PubMed

Uckun FM, Gaynon PS, Stram DO, Sensel MG, Sarquis MB, Willoughby M. Bone marrow leukemic progenitor cell content in pediatric T-lineage acute lymphoblastic leukemia patients with an isolated extramedullary first relapse. Leuk Lymphoma. 2001 Jan; 40(3-4):279-85. View in: PubMed

Gaynon PS, Trigg ME, Heerema NA, Sensel MG, Sather HN, Hammond GD, Bleyer WA. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia. 2000 Dec; 14(12):2223-33. View in: PubMed

Schrappe M, Camitta B, Pui CH, Eden T, Gaynon P, Gustafsson G, Janka-Schaub GE, Kamps W, Masera G, Sallan S, Tsuchida M, Vilmer E. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia. 2000 Dec; 14(12):2193-4. View in: PubMed

Heerema NA, Sather HN, Sensel MG, Lee MK, Hutchinson RJ, Nachman JB, Reaman GH, Lange BJ, Steinherz PG, Bostrom BC, Gaynon PS, Uckun FM. Abnormalities of chromosome bands 13q12 to 13q14 in childhood acute lymphoblastic leukemia. J Clin Oncol. 2000 Nov 15; 18(22):3837-44. View in: PubMed

Gaynon PS. Prognostic factors in acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2000 Sep-Oct; 22(5):403-4. View in: PubMed

Uckun FM, Stork L, Seibel N, Sarquis M, Bedros C, Sather H, Sensel M, Reaman GH, Gaynon PS. Residual bone marrow leukemic progenitor cell burden after induction chemotherapy in pediatric patients with acute lymphoblastic leukemia. Clin Cancer Res. 2000 Aug; 6(8):3123-30. View in: PubMed

Heerema NA, Sather HN, Sensel MG, Zhang T, Hutchinson RJ, Nachman JB, Lange BJ, Steinherz PG, Bostrom BC, Reaman GH, Gaynon PS, Uckun FM. Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (> 50 chromosomes). J Clin Oncol. 2000 May; 18(9):1876-87. View in: PubMed

Heerema NA, Sather HN, Sensel MG, Lee MK, Hutchinson R, Nachman JB, Lange BJ, Steinherz PG, Bostrom B, Gaynon PS, Uckun FM. Prognostic significance of cytogenetic abnormalities of chromosome arm 12p in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group. Cancer. 2000 Apr 15; 88(8):1945-54. View in: PubMed

Aricò M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A, Gaynon P, Silverman L, Janka-Schaub G, Kamps W, Pui CH, Masera G. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000 Apr 6; 342(14):998-1006. View in: PubMed

Heerema NA, Sather HN, Sensel MG, Lee MK, Hutchinson R, Lange BJ, Bostrom BC, Nachman JB, Steinherz PG, Gaynon PS, Uckun FM. Clinical significance of deletions of chromosome arm 6q in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group. Leuk Lymphoma. 2000 Feb; 36(5-6):467-78. View in: PubMed

Trigg ME, Steinherz PG, Chappell R, Johnstone HS, Gaynon PS, Kersey JH, Cherlow JM, Grossman NJ, Sather HN, Hammond GD. Early testicular biopsy in males with acute lymphoblastic leukemia: lack of impact on subsequent event-free survival. J Pediatr Hematol Oncol. 2000 Jan-Feb; 22(1):27-33. View in: PubMed

Heerema NA, Nachman JB, Sather HN, Sensel MG, Lee MK, Hutchinson R, Lange BJ, Steinherz PG, Bostrom B, Gaynon PS, Uckun F. Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the children's cancer group. Blood. 1999 Dec 15; 94(12):4036-45. View in: PubMed

Sun L, Goodman PA, Wood CM, Crotty ML, Sensel M, Sather H, Navara C, Nachman J, Steinherz PG, Gaynon PS, Seibel N, Vassilev A, Juran BD, Reaman GH, Uckun FM. Expression of aberrantly spliced oncogenic ikaros isoforms in childhood acute lymphoblastic leukemia. J Clin Oncol. 1999 Dec; 17(12):3753-66. View in: PubMed

Uckun FM, Gaynon PS, Stram DO, Sensel MG, Sarquis MB, Lazarus KH, Willoughby M. Paucity of leukemic progenitor cells in the bone marrow of pediatric B-lineage acute lymphoblastic leukemia patients with an isolated extramedullary first relapse. Clin Cancer Res. 1999 Sep; 5(9):2415-20. View in: PubMed

Heerema NA, Sather HN, Sensel MG, Liu-Mares W, Lange BJ, Bostrom BC, Nachman JB, Steinherz PG, Hutchinson R, Gaynon PS, Arthur DC, Uckun FM. Association of chromosome arm 9p abnormalities with adverse risk in childhood acute lymphoblastic leukemia: A report from the Children's Cancer Group. Blood. 1999 Sep 1; 94(5):1537-44. View in: PubMed

Sun L, Crotty ML, Sensel M, Sather H, Navara C, Nachman J, Steinherz PG, Gaynon PS, Seibel N, Mao C, Vassilev A, Reaman GH, Uckun FM. Expression of dominant-negative Ikaros isoforms in T-cell acute lymphoblastic leukemia. Clin Cancer Res. 1999 Aug; 5(8):2112-20. View in: PubMed

Uckun FM, Nachman JB, Sather HN, Sensel MG, Kraft P, Steinherz PG, Lange B, Hutchinson R, Reaman GH, Gaynon PS, Heerema NA. Poor treatment outcome of Philadelphia chromosome-positive pediatric acute lymphoblastic leukemia despite intensive chemotherapy. Leuk Lymphoma. 1999 Mar; 33(1-2):101-6. View in: PubMed

Uckun FM, Waurzyniak BJ, Sather HN, Sensel MG, Chelstrom L, Nachman J, Gaynon PS, Bostrom B, Ek O, Sarquis M, Steinherz PG, Reaman GH. Prognostic significance of T-lineage leukemic cell growth in SCID mice: a Children's Cancer Group study. Leuk Lymphoma. 1999 Feb; 32(5-6):475-87. View in: PubMed

Reaman GH, Sposto R, Sensel MG, Lange BJ, Feusner JH, Heerema NA, Leonard M, Holmes EJ, Sather HN, Pendergrass TW, Johnstone HS, O'Brien RT, Steinherz PG, Zeltzer PM, Gaynon PS, Trigg ME, Uckun FM. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. J Clin Oncol. 1999 Feb; 17(2):445-55. View in: PubMed

Gaynon PS, Carrel AL. Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia. Adv Exp Med Biol. 1999; 457:593-605. View in: PubMed

Moskowitz IP, Gaynon PS, Shahidi NT, Cripe TP. Low-dose cyclosporin A therapy in children with refractory immune thrombocytopenic purpura. J Pediatr Hematol Oncol. 1999 Jan-Feb; 21(1):77-9. View in: PubMed

Waurzyniak BJ, Heerema N, Sensel MG, Gaynon PS, Kraft P, Sather HN, Chelstrom L, Reaman GH, Uckun FM. Distinct in vivo engraftment and growth patterns of t(1;19)+/E2A-PBX1+ and t(9;22)+/BCR-ABL+ human leukemia cells in SCID mice. Leuk Lymphoma. 1998 Dec; 32(1-2):77-87. View in: PubMed

Uckun FM, Nachman JB, Sather HN, Sensel MG, Kraft P, Steinherz PG, Lange B, Hutchinson R, Reaman GH, Gaynon PS, Heerema NA. Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: a report from the Children's Cancer Group. Cancer. 1998 Nov 1; 83(9):2030-9. View in: PubMed

Ek O, Gaynon P, Zeren T, Chelstrom LM, Myers DE, Uckun FM. Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase. Leuk Lymphoma. 1998 Sep; 31(1-2):143-9. View in: PubMed

Uckun FM, Sather HN, Waurzyniak BJ, Sensel MG, Chelstrom L, Ek O, Sarquis MB, Nachman J, Bostrom B, Reaman GH, Gaynon PS. Prognostic significance of B-lineage leukemic cell growth in SCID mice: a Children's Cancer Group Study. Leuk Lymphoma. 1998 Aug; 30(5-6):503-14. View in: PubMed

Uckun FM, Herman-Hatten K, Crotty ML, Sensel MG, Sather HN, Tuel-Ahlgren L, Sarquis MB, Bostrom B, Nachman JB, Steinherz PG, Gaynon PS, Heerema N. Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation. Blood. 1998 Aug 1; 92(3):810-21. View in: PubMed

Uckun FM, Waurzyniak BJ, Sensel MG, Chelstrom L, Crotty ML, Gaynon PS, Reaman GH. Primary blasts from infants with acute lymphoblastic leukemia cause overt leukemia in SCID mice. Leuk Lymphoma. 1998 Jul; 30(3-4):269-77. View in: PubMed

Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN, Wolff L, Uckun FM, Gaynon PS. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998 Jun 4; 338(23):1663-71. View in: PubMed

Gaynon PS, Qu RP, Chappell RJ, Willoughby ML, Tubergen DG, Steinherz PG, Trigg ME. Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse--the Children's Cancer Group Experience. Cancer. 1998 Apr 1; 82(7):1387-95. View in: PubMed

Heerema NA, Sather HN, Sensel MG, Kraft P, Nachman JB, Steinherz PG, Lange BJ, Hutchinson RS, Reaman GH, Trigg ME, Arthur DC, Gaynon PS, Uckun FM. Frequency and clinical significance of cytogenetic abnormalities in pediatric T-lineage acute lymphoblastic leukemia: a report from the Children's Cancer Group. J Clin Oncol. 1998 Apr; 16(4):1270-8. View in: PubMed

Nachman J, Sather HN, Cherlow JM, Sensel MG, Gaynon PS, Lukens JN, Wolff L, Trigg ME. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group. J Clin Oncol. 1998 Mar; 16(3):920-30. View in: PubMed

Uckun FM, Sensel MG, Sather HN, Gaynon PS, Arthur DC, Lange BJ, Steinherz PG, Kraft P, Hutchinson R, Nachman JB, Reaman GH, Heerema NA. Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group. J Clin Oncol. 1998 Feb; 16(2):527-35. View in: PubMed

Uckun FM, Sensel MG, Sun L, Steinherz PG, Trigg ME, Heerema NA, Sather HN, Reaman GH, Gaynon PS. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood. 1998 Feb 1; 91(3):735-46. View in: PubMed

Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, Johnstone HS, Sather HN, Trigg ME, Uckun FM, Bleyer WA. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group. Cancer. 1998 Feb 1; 82(3):600-12. View in: PubMed

Gaynon PS, Desai AA, Bostrom BC, Hutchinson RJ, Lange BJ, Nachman JB, Reaman GH, Sather HN, Steinherz PG, Trigg ME, Tubergen DG, Uckun FM. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer. 1997 Nov 1; 80(9):1717-26. View in: PubMed

Uckun FM, Sather H, Gaynon P, Arthur D, Nachman J, Sensel M, Steinherz P, Hutchinson R, Trigg M, Reaman G. Prognostic significance of the CD10+CD19+CD34+ B-progenitor immunophenotype in children with acute lymphoblastic leukemia: a report from the Children's Cancer Group. Leuk Lymphoma. 1997 Nov; 27(5-6):445-57. View in: PubMed

Ettinger LJ, Ivy P, Gaynon PS, Ettinger AG, Liu-Mares W, Krailo MD. A phase II study of carboplatin as a treatment for children with acute leukemia recurring in bone marrow: a report of the Children's Cancer Group. Cancer. 1997 Jul 15; 80(2):311-6. View in: PubMed

Uckun FM, Sather HN, Gaynon PS, Arthur DC, Trigg ME, Tubergen DG, Nachman J, Steinherz PG, Sensel MG, Reaman GH. Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 1997 Jul 1; 90(1):28-35. View in: PubMed

Schultz KR, Massing B, Spinelli JJ, Gaynon PS, Wadsworth L. Importance of the day 7 bone marrow biopsy as a prognostic measure of the outcome in children with acute lymphoblastic leukemia. Med Pediatr Oncol. 1997 Jul; 29(1):16-22. View in: PubMed

Uckun FM, Gaynon PS, Sensel MG, Nachman J, Trigg ME, Steinherz PG, Hutchinson R, Bostrom BC, Sather HN, Reaman GH. Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study. J Clin Oncol. 1997 Jun; 15(6):2214-21. View in: PubMed

Gaynon PS, Crotty ML, Sather HN, Bostrom BC, Nachman JB, Steinherz PG, Heerema NA, Sarquis M, Tuel-Ahlgren L, Uckun FM. Expression of BCR-ABL, E2A-PBX1, and MLL-AF4 fusion transcripts in newly diagnosed children with acute lymphoblastic leukemia: a Children's Cancer Group initiative. Leuk Lymphoma. 1997 Jun; 26(1-2):57-65. View in: PubMed

Nachman J, Sather HN, Gaynon PS, Lukens JN, Wolff L, Trigg ME. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. J Clin Oncol. 1997 Jun; 15(6):2222-30. View in: PubMed

Uckun FM, Yang Z, Sather H, Steinherz P, Nachman J, Bostrom B, Crotty L, Sarquis M, Ek O, Zeren T, Tubergen D, Reaman G, Gaynon P. Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children's Cancer Group Study. Blood. 1997 May 15; 89(10):3769-77. View in: PubMed

Uckun FM, Gaynon P, Sather H, Arthur D, Trigg M, Tubergen D, Nachman J, Steinherz P, Sensel MG, Reaman GR. Clinical features and treatment outcome of children with biphenotypic CD2+ CD19+ acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 1997 Apr 1; 89(7):2488-93. View in: PubMed

Ettinger LJ, Ettinger AG, Avramis VI, Gaynon PS. [In Process Citation]. BioDrugs. 1997 Jan; 7(1):30-9. View in: PubMed

Uckun FM, Reaman G, Steinherez PG, Arthur DC, Sather H, Trigg M, Tubergen D, Gaynon P. Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children's Cancer Group Study. Leuk Lymphoma. 1996 Dec; 24(1-2):57-70. View in: PubMed

Uckun FM, Steinherz PG, Sather H, Trigg M, Arthur D, Tubergen D, Gaynon P, Reaman G. CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 1996 Dec 1; 88(11):4288-95. View in: PubMed

Cherlow JM, Sather H, Steinherz P, Gaynon P, Tubergen D, Trigg M, Novak L, Bleyer WA. Craniospinal irradiation for acute lymphoblastic leukemia with central nervous system disease at diagnosis: a report from the Children's Cancer Group. Int J Radiat Oncol Biol Phys. 1996 Aug 1; 36(1):19-27. View in: PubMed

Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, Johnstone HS, Sather HN, Trigg ME, Chappell R, Hammond D, Bleyer WA. Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group. J Clin Oncol. 1996 Feb; 14(2):389-98. View in: PubMed

Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn EL, Link M, Murphy S, Pui CH, Pullen J, Reamon G, Sallan SE, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Ungerleider R. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996 Jan; 14(1):18-24. View in: PubMed

Uckun FM, Sather H, Reaman G, Shuster J, Land V, Trigg M, Gunther R, Chelstrom L, Bleyer A, Gaynon P, et al. Leukemic cell growth in SCID mice as a predictor of relapse in high-risk B-lineage acute lymphoblastic leukemia. Blood. 1995 Feb 15; 85(4):873-8. View in: PubMed

Gaynon PS, Lustig RH. The use of glucocorticoids in acute lymphoblastic leukemia of childhood. Molecular, cellular, and clinical considerations. J Pediatr Hematol Oncol. 1995 Feb; 17(1):1-12. View in: PubMed

Gaynon PS. Carboplatin in pediatric malignancies. Semin Oncol. 1994 Oct; 21(5 Suppl 12):65-76. View in: PubMed

Ettinger LJ, Gaynon PS, Krailo MD, Ru N, Baum ES, Siegel SE, Hammond GD. A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Childrens Cancer Group. Cancer. 1994 Feb 15; 73(4):1297-301. View in: PubMed

Cherlow JM, Steinherz PG, Sather HN, Gaynon PS, Grossman NJ, Kersey JH, Johnstone HS, Breneman JC, Trigg ME, Hammond GD. The role of radiation therapy in the treatment of acute lymphoblastic leukemia with lymphomatous presentation: a report from the Childrens Cancer Group. Int J Radiat Oncol Biol Phys. 1993 Dec 1; 27(5):1001-9. View in: PubMed

Gaynon PS, Steinherz PG, Bleyer WA, Ablin AR, Albo VC, Finklestein JZ, Grossman NJ, Novak LJ, Pyesmany AF, Reaman GH, et al. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106. J Clin Oncol. 1993 Nov; 11(11):2234-42. View in: PubMed

Ettinger LJ, Krailo MD, Gaynon PS, Hammond GD. A phase I study of carboplatin in children with acute leukemia in bone marrow relapse. A report from the Childrens Cancer Group. Cancer. 1993 Aug 1; 72(3):917-22. View in: PubMed

Nachman J, Sather HN, Buckley JD, Gaynon PS, Steinherz PG, Tubergen DG, Lampkin BC, Hammond GD. Young adults 16-21 years of age at diagnosis entered on Childrens Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatment. Cancer. 1993 May 15; 71(10 Suppl):3377-85. View in: PubMed

Gaynon PS, Steinherz PG, Bleyer WA, Finklestein JZ, Miller DR, Reaman GH, Sather HN, Hammond GD. Association of delivered drug dose and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol. 1991; 19(4):221-7. View in: PubMed

Zeltzer PM, Epport K, Nelson MD, Huff K, Gaynon P. Prolonged response to carboplatin in an infant with brain stem glioma. Cancer. 1991 Jan 1; 67(1):43-7. View in: PubMed

Kowal-Vern A, Johnson FL, Trujillo Y, Nachman J, Radhakrishnan J, Conard P, Gaynon P. Granulocytic sarcoma of the ileum treated by bone marrow transplantation. Am J Pediatr Hematol Oncol. 1991; 13(1):34-8. View in: PubMed

Gaynon PS, Ettinger LJ, Baum ES, Siegel SE, Krailo MD, Hammond GD. Carboplatin in childhood brain tumors. A Children's Cancer Study Group Phase II trial. Cancer. 1990 Dec 15; 66(12):2465-9. View in: PubMed

Gaynon PS. Primary treatment of childhood acute lymphoblastic leukemia of non-T cell lineage (including infants). Hematol Oncol Clin North Am. 1990 Oct; 4(5):915-36. View in: PubMed

Gaynon PS, Bleyer WA, Steinherz PG, Finklestein JZ, Littman P, Miller DR, Reaman G, Sather H, Hammond GD. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol. 1990; 18(4):273-9. View in: PubMed

Gaynon PS, Steinherz PG, Bleyer WA, Ablin AR, Albo VC, Finklestein JZ, Grossman NJ, Littman PS, Novak LT, Pyesmany AF, et al. Intensive therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features. Early conclusions of study CCG-106 by the Childrens Cancer Study Group. Lancet. 1988 Oct 22; 2(8617):921-4. View in: PubMed

Maurer HS, Steinherz PG, Gaynon PS, Finklestein JZ, Sather HN, Reaman GH, Bleyer WA, Hammond GD. The effect of initial management of hyperleukocytosis on early complications and outcome of children with acute lymphoblastic leukemia. J Clin Oncol. 1988 Sep; 6(9):1425-32. View in: PubMed

Gaynon PS, Bleyer WA, Steinherz PG, Finklestein JZ, Littman PS, Miller DR, Reaman GH, Sather HN, Hammond GD. Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features. Report of Children's Cancer Study Group Study CCG-193P. Am J Pediatr Hematol Oncol. 1988; 10(1):42-50. View in: PubMed

Reaman GH, Steinherz PG, Gaynon PS, Bleyer WA, Finklestein JZ, Evans R, Miller DR, Sather HN, Hammond GD. Improved survival of infants less than 1 year of age with acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Cancer Treat Rep. 1987 Nov; 71(11):1033-8. View in: PubMed

Gaynon PS, Ettinger LJ, Moel D, Siegel SE, Baum ES, Krivit W, Hammond GD. Pediatric phase I trial of carboplatin: a Childrens Cancer Study Group report. Cancer Treat Rep. 1987 Nov; 71(11):1039-42. View in: PubMed

Gaynon PS, Steinherz PG, Reaman GH, Bleyer WA, Sather H, Hammond GD. Strategies for the treatment of children with acute lymphoblastic leukemia and unfavorable presenting features. Haematol Blood Transfus. 1987; 30:167-72. View in: PubMed

Gaynon PS, Baum ES, Samsel C, Sather H. Microcomputer-assisted data management for multiinstitutional pediatric clinical cancer trials. Am J Pediatr Hematol Oncol. 1987; 9(1):33-41. View in: PubMed

Steinherz PG, Gaynon P, Miller DR, Reaman G, Bleyer A, Finklestein J, Evans RG, Meyers P, Steinherz LJ, Sather H, et al. Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen--a new intensive therapy protocol: a report from the Childrens Cancer Study Group. J Clin Oncol. 1986 May; 4(5):744-52. View in: PubMed

Gaynon PS, Baum ES. Continuous infusion of 5-azacytidine as induction for acute nonlymphocytic leukemia in patients with previous exposure to 5-azacytidine. Oncology. 1983; 40(3):192-4. View in: PubMed

Gaynon PS, Baum ES, Krivit W, Hammond D. Phase II trial of prednimustine in children with recurrent cancer: a Children's Cancer Study Group report. Cancer Treat Rep. 1982 Jul; 66(7):1583-4. View in: PubMed

Baum ES, Gaynon P, Greenberg L, Krivit W, Hammond D. Phase II trail cisplatin in refractory childhood cancer: Children's Cancer Study Group Report. Cancer Treat Rep. 1981 Sep-Oct; 65(9-10):815-22. View in: PubMed

Powered bySC CTSI